Activity of drug combinations against dormant Mycobacterium tuberculosis.
Aerobic (5-day-old cultures) and nonreplicating (dormant) Mycobacterium tuberculosis (5-, 12-, and 19-day-old cultures) bacteria were treated with rifampin (R), moxifloxacin (MX), metronidazole (MZ), amikacin (AK), or capreomycin (CP) for 7, 14, and 21 days. R-MX-MZ-AK and R-MX-MZ-CP killed both aerobic and dormant bacilli in 21 days, as shown by lack of regrowth in solid and liquid media. R-MX-MZ-AK and R-MX-MZ-CP also caused a strong decrease of nonreplicating bacilli in 7 days in a cell-based dormancy model.
Filippini
Perla
P
Dipartimento di Malattie Infettive, Parassitarie e Immunomediate, Istituto Superiore di Sanità, Viale Regina Elena, Rome, Italy.
Iona
Elisabetta
E
Piccaro
Giovanni
G
Peyron
Pascale
P
Neyrolles
Olivier
O
Fattorini
Lanfranco
L
D016475:3T3 Cells; D017667:Adipocytes / Q000187:drug effects / Q000382:microbiology; D000583:Amikacin / Q000008:administration & dosage; D000818:Animals; D000995:Antitubercular Agents / Q000008:administration & dosage*; D001372:Aza Compounds / Q000008:administration & dosage; D002207:Capreomycin / Q000008:administration & dosage; D015169:Colony Count, Microbial; D004338:Drug Combinations; D024881:Drug Resistance, Bacterial; D024841:Fluoroquinolones; D006801:Humans; D066298:In Vitro Techniques; D055985:Latent Tuberculosis / Q000188:drug therapy* / Q000382:microbiology*; D008795:Metronidazole / Q000008:administration & dosage; D051379:Mice; D008826:Microbial Sensitivity Tests; D008954:Models, Biological; D000077266:Moxifloxacin; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000254:growth & development*; D011804:Quinolines / Q000008:administration & dosage; D012293:Rifampin / Q000008:administration & dosage
D000995:Antitubercular Agents; D001372:Aza Compounds; D004338:Drug Combinations; D024841:Fluoroquinolones; D011804:Quinolines; D002207:Capreomycin; D008795:Metronidazole; D000583:Amikacin; D000077266:Moxifloxacin; D012293:Rifampin